Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

BACKGROUND: In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy. Here we report a sub-analysis of the Japa...

Descripción completa

Detalles Bibliográficos
Autores principales: Minakata, Daisuke, Ishida, Tadao, Ando, Kiyoshi, Suzuki, Rikio, Tanaka, Junji, Hagiwara, Shotaro, Ananthakrishnan, Revathi, Kuwayama, Shigeki, Nishio, Mitsufumi, Kanda, Yoshinobu, Suzuki, Kenshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121508/
https://www.ncbi.nlm.nih.gov/pubmed/36690910
http://dx.doi.org/10.1007/s12185-023-03538-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121508/
https://www.ncbi.nlm.nih.gov/pubmed/36690910
http://dx.doi.org/10.1007/s12185-023-03538-6

Ejemplares similares